Objective Renal cytochrome P450 3A5 (CYP3A5) activity has been associated with blood pressure and salt sensitivity in humans. We determined whether CYP3A5 polymorphisms are associated with ambulatory blood pressure (ABP) and with glomerular filtration rate (GFR) in African families.
Introduction
The cytochrome P450 enzymes are classified into families and subfamilies based on the sequence of their amino acids [1] . Enzymes of the human CYP3A family are involved in the metabolism of endogenous substrates, such as steroids, and in the metabolism of many drugs. The genes of the CYP3A family (3A4, 3A43, 3A5 and 3A7) cluster on chromosome 7q21-7q22.1 [2] and show organ-specific patterns of expression [3] [4] [5] . Only the CYP3A5 gene is expressed in the human kidney [6, 7] .
The CYP3A5 enzyme catalyzes the conversion of cortisol to its 6b-hydroxy metabolite in the liver [3] and also accounts for most of the 6b-hydroxylase activity in mammals, including humans [8] . Renal CYP3A5 enzymatic activity has been shown to correlate with systolic blood pressure (BP) in the rat [9] and selective inhibitors of the CYP3A5 enzyme have been found to decrease the level of 6b-hydrocortisol and decrease BP in the rat [10] . These data suggest a possible link between the CYP3A5 gene and BP regulation, which could be mediated by an enhanced renal tubular sodium reabsorption through increased levels of 6b-hydrocortisol.
Several CYP3A5 alleles have been described (www.imm. ki.se/CYPalleles/cyp3a5.htm, accession date 13 May 2005) that show different levels of expression and are associated with different amounts of CYP3A5 enzyme [11, 12] . Only CYP3A5 Ã 1 carriers express large amounts of CYP3A5 messenger RNA (mRNA) and protein [11] . In Caucasians, a decreased CYP3A5 enzymatic activity can be largely explained by the frequent presence of allele Ã 3, while in African Americans alleles Ã 6 and Ã 7 can be found in a significant proportion of subjects with low CYP3A5 activity [11, 13] . It has been postulated that the CYP3A5 Ã 1 allele could confer a selective advantage in equatorial populations experiencing water shortage by increasing sodium retention [11] . Thompson et al. [14] , who measured only alleles Ã 1 and Ã 3, have shown that the frequency of the CYP3A5 Ã 3 allele varies broadly across populations, which implies a complementary pattern between CYP3A5 Ã 1 and CYP3A5 Ã 3 alleles, and that this variation is positively correlated with geographical distance from the equator.
Recently Givens et al. [15] , who measured only alleles Ã 1 and Ã 3, found an association between the CYP3A5 Ã 1 allele and both office systolic BP and creatinine clearance in a small group of healthy young African Americans. Furthermore, Ho et al. [16] found that the CYP3A5 Ã 1 allele was associated with hypertension in individuals of African descent but not in Caucasians. Unlike Givens et al. [15] , Ho et al. [16] found no association of CYP3A5 polymorphisms (alleles Ã 1 and Ã 3) with glomerular filtration rate (GFR) estimated by creatinine clearance.
In this report, we analyzed the association of CYP3A5 polymorphisms (i.e. alleles Ã 1, Ã 3, Ã 6 and Ã 7) with ambulatory BP and renal function in a sample of families of African descent that included both normotensive and hypertensive individuals.
Methods
The study took place in the Seychelles islands, which are populated predominantly by individuals of East African descent. Participants were recruited between August 1999 and January 2002. The study was approved by the Ethical Committees of the Ministry of Health in the Seychelles and of the Faculty of Medicine of the University of Lausanne (Switzerland). All participants provided written informed consent. Families were selected from an ongoing hypertension register that includes all patients with hypertension who attend primary health-care centers in the country. The selection process for families has been described previously [17] . Briefly, families were selected from the hypertension register if there were ! 2 full siblings with hypertension (i.e. average of three readings ! 140/90 mmHg). Seventy-six of the 135 screened families were found to be eligible, among which 375 individuals from 72 families of mean size 4.89 AE 2.93 (with 1-3 generations that included 89 sibships of mean size 4.01 AE 1.99) provided data for this analysis. Exclusion criteria were an age below 18 years, an inability to sign a written informed consent, and the presence of an acute medical condition (e.g. acute stroke or myocardial infarction within the past 6 months).
Antihypertensive therapy, if any, was stopped for 2 weeks before participants underwent BP measurement and blood and urine collections. Ambulatory BP was monitored using electronic Diasys devices (DIASYS Integra, Novacor SA, Rueil-Malmaison, France) placed on the left arm with an appropriately sized cuff. Additional methodological criteria have been described previously [18] . We used the average of 10 randomly selected daytime measures and 10 randomly selected night-time measures to have the same number of measures for each participant.
Participants were given plastic containers to collect urine for 24 h on their usual diet. Participants collected their urine on the same day as ambulatory BP monitoring was performed. Participants were examined in a study center after an overnight fast. Protocols began between 0700 and 0800 h in a quiet room with the subject lying on a bed for 1 h. Plasma renin activity (PRA) and aldosterone were measured using radioimmunoassays as previously described [19] . Urinary and plasma sodium and potassium concentrations were measured by flame photometry (IL-943, Instrumentation Laboratory, Milan, Italy). GFR was measured using two methods, namely a standard 2-h inulin clearance and a 24-h creatinine clearance [17] . Body surface area was calculated using the Dubois formula [20] . Fractional excretion of lithium (FELI) and fractional excretion of sodium (FENA) were obtained by dividing the lithium (or sodium) clearance by the inulin clearance. FELI is an indirect marker of proximal tubular sodium reabsorption [21] .
Genetic analyses DNA was isolated using standard methods from blood drawn into K-EDTA tubes and stored at 48C. The CYP3A5 Ã 3, Ã 6 and Ã 7 alleles were determined by realtime polymerase chain reaction (PCR) with TaqMan 1 . Allelic discrimination assays were performed on an ABI Prism 7000 (Applied Biosystems, Rotkreuz, Switzerland) according to the manufacturer's instructions. The 25 ml PCR mixture contained 12.5 ml TaqMan Universal PCR master mix (2 Â solution containing AmpliTaq Gold DNA polymerase, AmpErase UNG, dNTPs, and optimized buffer), 700 nmol/l forward primer, 800 nmol/l reverse primer, 2 mmol/l each probe, and 100 ng of DNA. After an activation step of AmpErase (508C, 2 min) and of AmpliTaq Gold enzyme activation (958C, 10 min), 35 PCR cycles were performed with 15 s at 928C and 1 min at 618C. For the CYP3A5 Ã 3 allele, the primers were 
Statistical analyses
Differences between CYP3A5 Ã 1 carriers and non-carriers were assessed using t-tests for continuous variables and x 2 tests for categorical variables. One-way ANOVA was used to compare means across genotypes. Based on findings from descriptive analyses in our sample, we used a dominant mode of action on BP for allele Ã 1 over alleles Ã 3, Ã 6 and Ã 7, and an additive mode for allele Ã 3 with alleles Ã 6 and Ã 7, that is, among CYP3A5 Ã 1 non-carriers. Using the ASSOC program in the S.A.G.E. [22] statistical software, we analyzed the association between BP and CYP3A5 alleles from the family data. ASSOC analyzes from pedigree data the association between a continuous trait and one or more covariates, in the presence of familial correlations on the assumption that a power transformation of the trait leads to multivariate normality across pedigree members. We corrected for ascertainment as described previously [18] . We tested all twoway interactions between covariates with main effects significant at the 5% level and the CYP3A5 alleles. Age, sex, body mass index (BMI), urinary sodium and potassium excretion, diabetes and smoking, as well as all two-way interactions significant at the 0.10 level, were included as covariates, in addition to the CYP3A5 alleles. Age and sex were forced into all multivariable models. Similar analyses were conducted to determine whether the CYP3A5 gene was a significant determinant of GFR, measured by inulin clearance and creatinine clearance [17] , for the subgroup of 294 individuals who had data available on these variates. We used non-parametric trend tests across age (or urinary sodium) tertiles by CYP3A5 Ã 1 carrier status. We conducted quantitative pedigree transmission disequilibrium tests (QTDT) [23] ; this is implemented in the ASSOC program by means of a transmitted allele indicator. The QTDT is used to detect whether an association is due to linkage (or not) by comparing, within families, the effects of alleles that heterozygous parents transmit to their offspring to those of alleles they do not so transmit.
Results
The frequency of the CYP3A5 Ã 1 allele was 38.5% among founders (i.e. individuals for whom data from their parents were not available) and 43.7% among all participants. Other allele and genotype frequencies in the sample data are listed in Table 1 . Participants' characteristics are shown in Table 2 . The 24-h urinary creatinine excretion (above 0.16 mmol/kg for all CYP3A5 genotypes) and urine volume (above 1.75 litres for all CYP3A5 genotypes) suggested adequate urine collection, on average. Among the 152 participants taken off treatment, 76 were on diuretics, 44 on beta-blockers, 73 on calcium-channel blockers and 47 on angiotensin-converting enzyme inhibitors. Sixty-six were on monotherapy and 86 on two or more drugs. Figure 1 shows daytime ambulatory BP across age tertiles. There was a significant positive trend in BP with age in CYP3A5 Ã 1 carriers (P < 0.001) but not in non-carriers (P > 0.05), for both systolic and diastolic daytime BP. Within each age tertile, the difference in mean daytime BP between CYP3A5 Ã 1 carriers and non-carriers was not significant. There was a significant positive trend in BP with night-time urinary sodium in CYP3A5 Ã 1 carriers (P < 0.001) but not in non-carriers (P > 0.05), for both systolic and diastolic night-time BP (data not shown). Within each night-time urinary sodium excretion tertile, the difference in mean night-time BP between CYP3A5 Ã 1 carriers and non-carriers was not significant. These results suggest that daytime BP was associated more strongly with age, and night-time BP more strongly with urinary sodium excretion, in CYP3A5 Ã 1 carriers than in noncarriers.
For daytime systolic BP (Table 3) , multiple linear regression analysis showed a significant interaction between age and CYP3A5 Ã 1 (regression coefficient AE SE: 0.801 AE 0.217, P ¼ 0.0002), and between age and CYP3A5 Ã 3 (0.395 AE 0.147, P ¼ 0.007), and significant main effects of alleles Ã 1 (À29.556 AE 10.014, P ¼ 0.003) and Ã 3 (À14.145 AE 6.665, P ¼ 0.034). For daytime diastolic BP, there was a significant age Â CYP3A5 interaction (0.203 AE 0.086, P ¼ 0.018) and a significant main effect for CYP3A5 Ã 1 (À8.186 AE 4.086, P ¼ 0.045), but not for CYP3A5 Ã 3. No significant interaction with age was observed for night-time BP. However, there was an interaction of BP with urinary sodium excretion, in particular in the subgroup of participants untreated at baseline (Table 3 ). These findings suggest that the associations between ambulatory BP and CYP3A5 are not the same during the day and at night. When GFR, measured using inulin clearance, was used as the dependent trait, multiple linear regression analysis showed a significant CYP3A5 Ã 1 main effect (regression coefficient AE SE ¼ À7.552 AE 3.767, P ¼ 0.045) ( Table 3 ). The CYP3A5 Ã 1 main effect on GFR was slightly reduced when adjusting for body surface area (regression coefficient AE SE ¼ À6.297 AE 3.747, P ¼ 0.093). The association between the CYP3A5 Ã 1 allele and GFR was weaker when GFR was based on the 24-h creatinine clearance (Table 3 ) and adjustment for body surface area further decreased the CYP3A5 Ã 1 effect (regression coefficient AE SE ¼ À3.108 AE 4.160, P ¼ 0.455).
For the relationship between FELI (as the dependent trait) and age, there was a significant interaction between the CYP3A5 Ã 1 allele and age (Fig. 2) . No such interaction was found between the CYP3A5 Ã 3 allele and age. This indicates that CYP3A5 Ã 1 non-carriers decreased their proximal tubular sodium reabsorption with age, while CYP3A5 Ã 1 carriers did not.
Although the number of informative individuals (i.e. offspring with at least one heterozygous parent for allele Ã 1) was small (n = 36), the QTDT suggested association due to linkage of allele Ã 1 to ambulatory SBP (P ¼ 0.06/0.15 and P ¼ 0.11/0.29, for daytime/ night-time SBP and DBP, respectively). Because of the small number of informative individuals, we could not meaningfully assess interactions within QTDT analyses. Moreover, there was also evidence for association due to linkage of allele Ã 1 to GFR using inulin clearance (n ¼ 22, P ¼ 0.05), but not using creatinine clearance (P ¼ 0.77). These results suggest that, for each trait, the associations between CYP3A5 and SBP, and between CYP3A5 and GFR, are also due to linkage between the trait locus and the marker locus.
Discussion
To our knowledge, the present study is the largest to date to analyze the association between the CYP3A5 gene and ambulatory BP, and between the CYP3A5 gene and GFR, Pooled sex-specific age tertiles
Mean ambulatory daytime blood pressure by pooled sex-specific age tertiles. Solid dots represent mean daytime blood pressure values, dashed/solid vertical lines represent 95% confidence intervals for noncarriers/carriers of the CYP3A5 Ã 1 allele, respectively. SBP, systolic blood pressure, DBP, diastolic blood pressure. Numbers below each tertile are mean age (in years).
among individuals of African descent. Although the CYP3A5 gene has already been associated with BP in humans [15, 16] , we provide new insight on this relationship, based on extensive genotypic and phenotypic characterization. In particular, we showed that age and urinary sodium excretion modify the association between the CYP3A5 alleles and BP (i.e. that this association is more marked in older persons for daytime BP and in persons with high urinary sodium excretion for nighttime BP). Moreover, because we obtained similar results when restricting the analyses to those who were untreated at baseline, antihypertensive treatment did not appear to confound the observed associations in our study. However, this does not imply that antihypertensive treatment cannot be an important confounder in another setting.
We analyzed the CYP3A5 alleles Ã 1, Ã 3, Ã 6 and Ã 7. Only CYP3A5 Ã 1 carriers produce high levels of CYP3A5 mRNA [11] and express large amounts of CYP3A5. In addition, allele Ã 1 has been associated with the CYP3A5 enzymatic activity in kidneys of persons of African descent [15] . We found that the CYP3A5 Ã 1 allele (43.7%) was more frequent than the Ã 3 allele (36.1%) in our population of African descent, in contrast to Caucasian populations, which is in agreement with previously published studies [11, 24] . The CYP3A5 Ã 6 allele generates a splice variant mRNA in which exon 7 is deleted, which causes the encoded protein to be truncated at amino acid 184 [11] . The CYP3A5 Ã 7 allele creates an insertion, which terminates the open reading frame of CYP3A5 at position 348 [13] . The CYP3A5 Ã 3 allele generates a cryptic splice site and alternative splicing which result in protein truncation and absence of CYP3A5. Because the splice site prediction score is less than one (0.9), small amounts of normally spliced CYP3A5 mRNA and resulting protein can be CYP3A5 association with blood pressure Bochud et al. 927 All regression models allowed for familial correlations and included as predictors age, sex, ascertainment and CYP3A5. In addition, daytime SBP was adjusted for the presence of diabetes and urinary Na; daytime DBP was adjusted for age squared; night-time SBP was adjusted for urine Na and K, and DBP for urine Na and K and age squared. The models for participants untreated at baseline included the same predictor variables as the models for the whole sample. The models for inulin and creatinine clearance included as predictors age, sex, ascertainment, body mass index (BMI), diabetes and CYP3A5 Sex-specific age quartiles (mean age in years)
Plot of fractional excretion of lithium (FELI) by pooled sex-specific age quartiles in CYP3A5 Ã 1 carriers versus non-carriers. Dots are adjusted FELI, i.e. FELI values obtained from linear models in ASSOC (hence allowing for familial correlations) including as predictors fractional excretion of sodium (FENA), age, sex, body mass index and ascertainment. P for interaction between CYP3A5 detected even in people homozygous for the CYP3A5 Ã 3 allele [11] .
Although crude BP levels were similar between carriers and non-carriers of the CYP3A5 Ã 1 allele, a significant positive interaction between CYP3A5 Ã 1 and age was found for both daytime ambulatory systolic and diastolic BP. Our results indicate that age is an effect modifier of the association between the CYP3A5 Ã 1 allele and daytime ambulatory BP, that is only CYP3A5 Ã 1 carriers demonstrate an age-related significant BP increase. CYP3A5 Ã 1 carriers tended to have higher BP levels despite a tendency toward lower urinary sodium excretion (i.e. a lower salt intake). The low urinary sodium excretion is likely reflecting a diet based mainly on fish, vegetables and unsalted rice, and poor in processed food. In rats, Warrington et al. [25] observed a significant increase with age of the enzymatic activity of one CYP3A isoform in the kidney, while CYP3A activity decreased with age in the liver. As renal CYP3A5 enzymatic activity has been shown to correlate with BP in the rat [9] , one could hypothesize that CYP3A5 enzymatic activity increases with age in human kidneys as well, consistent with our findings.
Age did not significantly interact with the relation between night-time ambulatory BP and CYP3A5 Ã 1. However, there was an interaction between CYP3A5 Ã 1 and urinary sodium excretion for night-time systolic and diastolic BP, which was stronger in the subgroup of participants untreated at baseline. These results suggest that CYP3A5 Ã 1 carriers tend to increase their night-time BP with increasing urinary sodium excretion (i.e. increasing dietary salt intake) more than CYP3A5 Ã 1 non-carriers. The reason why age modified the relation between daytime BP and CYP3A5 Ã 1, while urinary sodium excretion modified the relation between night-time BP and CYP3A5 Ã 1, may be the confounding effect of posturerelated neuro-hormonal changes. Several studies have found a positive correlation between BP and urinary sodium excretion during the night but not during the day [26] [27] [28] . Therefore, considering that (1) salt sensitivity is related to the increase of BP with age [29] and (2) CYP3A5 Ã 1 carriers tended to have a higher age-associated BP increase despite lower urinary sodium excretion, both daytime and night-time results consistently suggest that CYP3A5 Ã 1 carriers could be more salt-sensitive than noncarriers.
We also found differences in renal sodium handling between CYP3A5 Ã 1 carriers and non-carriers. While FELI increased with age in subjects not carrying the CYP3A5 Ã 1 allele (i.e. the proximal tubular sodium reabsorption decreased with age), this relation was not found in carriers of the CYP3A5 Ã 1 allele. Given that proximal sodium reabsorption may be a determinant of the BP response to salt [21] , this result strengthens the view that the CYP3A5 Ã 1 allele is associated with salt sensitivity, as previously demonstrated by Ho et al. [16] .
Unlike allele Ã 1, which had a clearly dominant effect, allele Ã 3 appeared to act additively on BP in non-carriers of the CYP3A5 Ã 1 allele. Noticeably, individuals who carried two copies of the Ã 3 allele had a pattern of BP increase with age similar to that of carriers of the Ã 1 allele in our study. This observation might reflect the fact that, although only CYP3A5 Ã 1 carriers express large amounts of CYP3A5 mRNA and protein, homozygous CYP3A5 Ã 3 carriers also produce small amounts of normally spliced CYP3A5 mRNA and resulting protein [11] . This result is consistent with the finding by Ho et al. [16] Our study has some limitations. Its cross-sectional nature inherently cannot distinguish between cause and consequence. It will be important to further analyze the effect of carrying the Ã 1 allele on BP, salt-sensitivity and renal function in longitudinal studies. The small number of individuals informative for association due to linkage (because most pedigrees in our study had one or two missing parental genotypes) did not allow us to assess an interaction of age or urinary sodium excretion for the relation between BP and the CYP3A5 alleles using the QTDT. Also, we have not measured other genes of the CYP3A family, and cannot comment on their role. It is, however, unlikely that the closely located CYP3A4 gene could account for our findings, since a previous study found no expression of this gene in human kidney microsomes [15] . Nevertheless, we cannot exclude the possibility that an allele at another locus, in strong linkage disequilibrium with the CYP3A5 Ã 1 allele, could account for our observed associations.
In conclusion, age and urinary sodium excretion were significant effect modifiers of the association between the CYP3A5 Ã 1 allele and ambulatory BP. These findings stress the importance of accounting for these covariates. CYP3A5 Ã 1 carriers had a higher age-associated daytime BP increase than non-carriers, despite a tendency toward lower urinary sodium excretion. Considering that CYP3A5 Ã 1 carriers also showed an increased proximal tubular sodium reabsorption with age as compared to non-carriers, our data, consistent with findings by others, support the hypothesis that CYP3A5 Ã 1 carriers are more salt-sensitive than non-carriers. Given that enzymes of the CYP3A family are involved in the metabolism of many drugs, such as calcium-channel blockers [30] , this protein might also be involved in drug interactions, which emphasizes the need to explore the relation of this gene with BP further. Additional studies are needed to further investigate the association of CYP3A5 Ã 1 with renal function.
